Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Status:
Recruiting
Trial end date:
2028-12-20
Target enrollment:
Participant gender:
Summary
Background:
Prostate cancer is the second leading cause of cancer death in U.S. men. Radiation is an
effective treatment for most patients with localized prostate cancer, but sometimes the tumor
returns. Researchers want to see if a highly focused type of radiation can help. It is given
in only 5 treatments. It is called stereotactic body radiation therapy (SBRT).
Objective:
To study the maximum tolerated dose and side effects of stereotactic body radiation therapy
in people with a local recurrence of prostate cancer after radiation.
Eligibility:
Men at least 18 years old who have recurrent prostate cancer after radiation therapy and no
evidence of distant metastatic disease
Design:
Participants will be screened with blood tests, physical exam, and medical history. They may
also have:
Magnetic resonance imaging (MRI) scan of the prostate..
PET/CT scan. Participants will get an injection of 18F-DCFPyL for the PET scan. They will lie
very still on their back on the scanner table.
Small samples of prostate tumor tissue will be taken by a needle through the skin or rectum
to see if the cancer is in the prostate. Small metal seeds will be placed into the prostate
at the same time to help guide the radiation.
About 2 weeks later, participants will have a radiation treatment planning CT scan.
Participants will answer questions about their urine function, bowel function, erectile
function, and mood.
Participants will receive SBRT. They will have 5 radiation treatments over 2 weeks.
Participants will have follow-up visits. They will have a physical exam, blood tests, and
questionnaires.
Six months after ending SBRT, the 18F-DCFPyL PET/CT will be repeated.
Participantes will continue to have routine visits until two years after treatment is
completed....